Discussion stirs around Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) this week; here is what analysts are saying.

May 18, 2018 - By Vivian Currie

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Coverage

Among 2 analysts covering Sunesis Pharma (NASDAQ:SNSS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sunesis Pharma had 4 analyst reports since November 20, 2017 according to SRatingsIntel. On Monday, December 11 the stock rating was upgraded by Wells Fargo to “Buy”. The company was downgraded on Tuesday, December 5 by Wells Fargo. The firm has “Buy” rating given on Thursday, December 14 by Oppenheimer. Oppenheimer initiated Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rating on Monday, November 20. Oppenheimer has “Buy” rating and $7.0 target. Below is a list of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) latest ratings and price target changes.

14/12/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate
11/12/2017 Broker: Wells Fargo Rating: Buy Upgrade
05/12/2017 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
20/11/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0 Initiate

The stock increased 1.49% or $0.04 during the last trading session, reaching $2.73. About 56,382 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has declined 37.14% since May 18, 2017 and is downtrending. It has underperformed by 48.69% the S&P500.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $93.83 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

Another recent and important Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) news was published by Seekingalpha.com which published an article titled: “Sunesis Pharmaceuticals’ (SNSS) Management on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.